Former Undersecretary of Commerce for Intellectual Property and USPTO Director David J. Kappos will moderate a panel of legal experts who will discuss recent developments in the area of patent utility and its implications for biopharmaceutical innovation.  Speakers will provide perspectives on utility law in Canada, Europe, Japan and the US, while considering both innovative and generic perspectives.  The moderator plans to take questions from the audience toward the end of the hour-long panel discussion.

To date, 18 pharmaceutical patents have been rendered invalid or unenforceable in Canada on the grounds of a lack of utility, despite their approval by Health Canada for the use claimed in the patents’ applications.  Arguing that Canada’s utility requirement is unique among OECD countries, and runs counter to Canada’s obligations to numerous international trade agreements, will be Patrick Kierans, Senior Partner, Norton Rose (Toronto); arguing that these invalidations reflect flawed patent applications, and sound patent law in Canada, will be Tim Gilbert, Partner, Gilberts LLP (Toronto). Rounding out the discussion and providing global context will be Bert Oosting, Partner, Hogan Lovells (Amsterdam) and Takashi Fujita, with Akabe, Ikubo & Katayama (Tokyo).Moderating the discussion, and providing a US perspective will be David Kappos, Partner, Cravath Swain and Moore (New York).

Ability Level: All

Session ID: 2093

myBIO Chatter

Speakers (5)

User Takashi Fujita Akabe ABE, IKUBO & KATAYAMA
User Tim Gilbert Partner Gilberts, LLP
contact_6927 David Kappos Former Director of the USPTO, Partner Cravath, Swaine & Moore LLP
contact_10034 Patrick Kierans Senior Partner Norton Rose, LLP
User Bert Oosting Partner HoganLovells International LLP